Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:49 UTC |
---|
Update Date | 2022-03-07 02:51:38 UTC |
---|
HMDB ID | HMDB0014462 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Gefitinib |
---|
Description | Gefitinib, also known as iressa or ZD 1839, belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups. This leads to inappropriate activation of the anti-apoptotic Ras signalling cascade, eventually leading to uncontrolled cell proliferation. Gefitinib is a drug which is used for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies. Adverse drug reactions (ADRs) are acceptable for a potentially fatal disease. Gefitinib is a very strong basic compound (based on its pKa). In humans, gefitinib is involved in gefitinib action pathway. IPASS (IRESSA Pan-Asia Study) was a randomized, large-scale, double-blinded study which compared gefitinib vs. carboplatin/ paclitaxel as a first-line treatment in advanced NSCLC.IPASS studied 1,217 patients with confirmed adenocarcinoma histology who were former or never smokers. |
---|
Structure | COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1 InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27) |
---|
Synonyms | Value | Source |
---|
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline | ChEBI | Gefitinibum | ChEBI | Iressa | ChEBI | Irressat | ChEBI | N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine | ChEBI | ZD 1839 | ChEBI | ZD-1839 | ChEBI | ZD1839 | ChEBI | N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide | HMDB |
|
---|
Chemical Formula | C22H24ClFN4O3 |
---|
Average Molecular Weight | 446.902 |
---|
Monoisotopic Molecular Weight | 446.152096566 |
---|
IUPAC Name | N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine |
---|
Traditional Name | gefitinib |
---|
CAS Registry Number | 184475-35-2 |
---|
SMILES | COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1 |
---|
InChI Identifier | InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27) |
---|
InChI Key | XGALLCVXEZPNRQ-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Diazanaphthalenes |
---|
Sub Class | Benzodiazines |
---|
Direct Parent | Quinazolinamines |
---|
Alternative Parents | |
---|
Substituents | - Quinazolinamine
- Anisole
- Aniline or substituted anilines
- Alkyl aryl ether
- Aminopyrimidine
- Chlorobenzene
- Fluorobenzene
- Halobenzene
- Aryl chloride
- Aryl fluoride
- Aryl halide
- Monocyclic benzene moiety
- Morpholine
- Oxazinane
- Pyrimidine
- Benzenoid
- Imidolactam
- Heteroaromatic compound
- Tertiary aliphatic amine
- Tertiary amine
- Secondary amine
- Azacycle
- Dialkyl ether
- Ether
- Oxacycle
- Organonitrogen compound
- Hydrocarbon derivative
- Organooxygen compound
- Organic nitrogen compound
- Amine
- Organic oxygen compound
- Organofluoride
- Organochloride
- Organopnictogen compound
- Organohalogen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.027 g/L | Not Available | LogP | 3.2 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Gefitinib,1TMS,isomer #1 | COC1=CC2=NC=NC(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C)=C2C=C1OCCCN1CCOCC1 | 3453.5 | Semi standard non polar | 33892256 | Gefitinib,1TMS,isomer #1 | COC1=CC2=NC=NC(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C)=C2C=C1OCCCN1CCOCC1 | 3391.4 | Standard non polar | 33892256 | Gefitinib,1TMS,isomer #1 | COC1=CC2=NC=NC(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C)=C2C=C1OCCCN1CCOCC1 | 4893.7 | Standard polar | 33892256 | Gefitinib,1TBDMS,isomer #1 | COC1=CC2=NC=NC(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2C=C1OCCCN1CCOCC1 | 3644.1 | Semi standard non polar | 33892256 | Gefitinib,1TBDMS,isomer #1 | COC1=CC2=NC=NC(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2C=C1OCCCN1CCOCC1 | 3566.6 | Standard non polar | 33892256 | Gefitinib,1TBDMS,isomer #1 | COC1=CC2=NC=NC(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2C=C1OCCCN1CCOCC1 | 4869.5 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Gefitinib GC-MS (Non-derivatized) - 70eV, Positive | splash10-0uxr-9424700000-182dba69c82bee61cbe2 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Gefitinib GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Gefitinib LC-ESI-qTof , Positive-QTOF | splash10-0002-1511900000-d0570bedf59699989575 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gefitinib , positive-QTOF | splash10-00di-0193000000-38bb088cc8af6a0e12a4 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gefitinib , positive-QTOF | splash10-0002-1511900000-d0570bedf59699989575 | 2017-09-14 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Gefitinib 10V, Positive-QTOF | splash10-0002-0201900000-dafa6866c6b59a71a89e | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Gefitinib 20V, Positive-QTOF | splash10-0udi-2904200000-011d82a75223a5017b87 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Gefitinib 40V, Positive-QTOF | splash10-009l-9402000000-d87048e0478c6d231bfe | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Gefitinib 10V, Negative-QTOF | splash10-0002-0004900000-bb4c9a2e360df1c7e52e | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Gefitinib 20V, Negative-QTOF | splash10-014s-3019400000-c4f741a0f46f6e8edd9f | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Gefitinib 40V, Negative-QTOF | splash10-0uy0-3279000000-593bcb0bda5ac3068617 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Gefitinib 10V, Negative-QTOF | splash10-0002-0000900000-f5b40d44879371ef81fb | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Gefitinib 20V, Negative-QTOF | splash10-0f6t-0005900000-a102859e7a71e3a4e883 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Gefitinib 40V, Negative-QTOF | splash10-0udi-1029000000-4b9f808b7f687fe38a43 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Gefitinib 10V, Positive-QTOF | splash10-0002-0000900000-fc203d826511c11b8cd1 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Gefitinib 20V, Positive-QTOF | splash10-0fba-1901400000-c8c0d48bbd64a7e7fa9a | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Gefitinib 40V, Positive-QTOF | splash10-0uk9-9515200000-6abbaa993868c8b744f4 | 2021-09-22 | Wishart Lab | View Spectrum |
|
---|
General References | - Sordella R, Bell DW, Haber DA, Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004 Aug 20;305(5687):1163-7. Epub 2004 Jul 29. [PubMed:15284455 ]
- Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11. Epub 2004 Aug 25. [PubMed:15329413 ]
- (). FDA label . .
|
---|